Thymulin inhibits monocrotaline-induced pulmonary hypertension modulating interleukin-6 expression and suppressing p38 pathway

Endocrinology

Volumn 149, Issue 9, 2008, Pages 4367-4373

  Henriques Coelho, Tiago ^a   Oliveira, Sílvia Marta ^a   Moura, Rute S ^b   Roncon Albuquerque Jr , Roberto ^a   Neves, Ana Luísa ^a   Santos, Mário ^a   Nogueira Silva, Cristina ^b   Carvalho, Filipe La Fuente ^a   Brandão Nogueira, Ana ^a   Correia Pinto, Jorge ^b   Leite Moreira, Adelino F ^a,c  

^a University of Porto   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Institute of Pharmacology and Therapeutics   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; CHEMOKINE; CYTOKINE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCROTALINE; SODIUM CHLORIDE; THYMULIN; THYMUS HORMONE; UNCLASSIFIED DRUG; ZINC; ZINC PLUS CARBOXYMETHYLCELLULOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEMODYNAMICS; INFLAMMATION; MALE; MORPHOMETRICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

ANIMALS; CYTOKINES; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; HEART; HEMODYNAMICS; HYPERTENSION, PULMONARY; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LUNG; MALE; MAP KINASE SIGNALING SYSTEM; MONOCROTALINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; THYMIC FACTOR, CIRCULATING;

EID: 50449087582     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0018     Document Type: Article

References (47)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A 2004 Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl S):5S-12S
2. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J, Task Force 2004 Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25:2243-2278
3. Tuder RM, Groves B, Badesch DB, Voelkel NF 1994 Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275-285
4. Cool CD, Kennedy D, Voelkel NF, Tuder RM 1997 Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28:434-442
5. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D 1995 Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:1628-1631
6. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, Simonneau G, Emilie D, Humbert M 2002 CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165:1419-1425
7. Dorfmuller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, Capron F, Coulomb-Lhermine A, Marfaing-Koka A, Simonneau G, Emilie D, Humbert M 2002 Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 165:534-539
8. Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M 1998 Chemokine macrophage inflammatory protein-1α mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 114(Suppl):50S-51S
9. Bhargava A, Kumar A, Yuan N, Gewitz MH, Mathew R 1999 Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis 1:126-132
10. Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot JL, Simonneau G 1996 Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis 55:561-562
11. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN 2001 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163:498-502
12. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC 2007 Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 8:15
13. Suzuki C, Takahashi M, Morimoto H, Izawa A, Ise H, Hongo M, Hoshikawa Y, Ito T, Miyashita H, Kobayashi E, Shimada K, Ikeda U 2006 Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. Biochem Biophys Res Commun 349:781-788
14. Dorfmuller P, Perros F, Balabanian K, Humbert M 2003 Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358-363
15. Naeije R, Dewachter L 2007 [Animal models of pulmonary arterial hypertension.] Rev Mal Respir 24(4 Pt 1):481-496 (French)
16. Voelkel NF, Tuder RM, Bridges J, Arend WP 1994 Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 11:664-675
17. Miyata M, Sakuma F, Yoshimura A, Ishikawa H, Nishimaki T, Kasukawa R 1995 Pulmonary hypertension in rats. 2. Role of interleukin-6. Int Arch Allergy Immunol 108:287-291
18. Miyata M, Ito M, Sasajima T, Ohira H, Kasukawa R 2001 Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest 119:554-561
19. Deng H, Song MJ, Chu JT, Sun R 2002 Transcriptional regulation of the interleukin-6 gene of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J Virol 76:8252-8264
20. Bach JF, Dardenne M, Pleau JM, Rosa J 1976 [Biochemical characterization of a circulating thymic factor.] C R Acad Sci Hebd Seances Acad Sci D 283:1605-1607 (French)
21. Dardenne M, Pleau JM, Man NK, Bach JF 1977 Structural study of circulating thymic factor: a peptide isolated from pig serum. I. Isolation and purification. J Biol Chem 252:8040-8044
22. Pleau JM, Dardenne M, Blouquit Y, Bach JF 1977 Structural study of circulating thymic factor: a peptide isolated from pig serum. II. Amino acid sequence. J Biol Chem 252:8045-8047
23. Bach JF, Dardenne M, Pleau JM, Bach MA 1975 Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human. Ann NY Acad Sci 249:186-210
24. Dardenne M, Pleau JM, Nabarra B, Lefrancier P, Derrien M, Choay J, Bach JF 1982 Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci USA 79:5370-5373
25. Savino W, Huang PC, Corrigan A, Berrih S, Dardenne M 1984 Thymic hormone-containing cells. V. Immunohistological detection of metallothionein within the cells bearing thymulin (a zinc-containing hormone) in human and mouse thymuses. J Histochem Cytochem 32:942-946
26. Dardenne M, Savino W, Gagnerault MC, Itoh T, Bach JF 1989 Neuroendocrine control of thymic hormonal production. I. Prolactin stimulates in vivo and in vitro the production of thymulin by human and murine thymic epithelial cells. Endocrinology 125:3-12
27. Haddad JJ, Land SC, Saade NE, Safieh-Garabedian B 2000 Immunomodulatory potential of thymulin-Zn(2+) in the alveolar epithelium: amelioration of endotoxin-induced cytokine release and partial amplification of a cytoprotective IL-10-sensitive pathway. Biochem Biophys Res Commun 274:500-505
28. Yara S, Kawakami K, Kudeken N, Tohyama M, Teruya K, Chinen T, Awaya A, Saito A 2001 FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin Exp Immunol 124:77- 85
29. Kohda Y, Kawai Y, Iwamoto N, Matsunaga Y, Aiga H, Awaya A, Gemba M 2005 Serum thymic factor, FTS, attenuates cisplatin nephrotoxicity by suppressing cisplatin-induced ERK activation. Biochem Pharmacol 70:1408-1416
30. Kohda Y, Matsunaga Y, Yonogi K, Kawai Y, Awaya A, Gemba M 2005 Protective effect of serum thymic factor, FTS, on cephaloridine-induced nephrotoxicity in rats. Biol Pharm Bull 28:2087-2091
31. Varin A, Larbi A, Dedoussis GV, Kanoni S, Jajte J, Rink L, Monti D, Malavolta M, Marcellini F, Mocchegiani E, Herbein G, Fulop Jr T 2008 In vitro and in vivo effects of zinc on cytokine signalling in human T cells. Exp Gerontol 43:472-482
32. Prasad AS 2008 Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol 43:370-377
33. Oliver MA, Marsh JA 2003 In vivo thymulin treatments enhance avian lung natural killer cell cytotoxicity in response to infectious bronchitis virus. Int Immunopharmacol 3:107-113
34. Orringer DA, Staeheli P, Marsh JA 2002 The effects of thymulin on macrophage responsiveness to interferon-γ. Dev Comp Immunol 26:95-102
35. Kling DE, Lorenzo HK, Trbovich AM, Kinane TB, Donahoe PK, Schnitzer JJ 2002 MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs. Am J Physiol Lung Cell Mol Physiol 282:L370-L378
36. Henriques-Coelho T, Correia-Pinto J, Roncon-Albuquerque Jr R, Baptista MJ, Lourenco AP, Oliveira SM, Brandao-Nogueira A, Teles A, Fortunato JM, Leite-Moreira AF 2004 Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 287:H2885-H2890
37. Roth RA, Reindel JF 1991 Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. Adv Exp Med Biol 283:477-487
38. Lu J, Shimpo H, Shimamoto A, Chong AJ, Hampton CR, Spring DJ, Yada M, Takao M, Onoda K, Yada I, Pohlman TH, Verrier ED 2004 Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats. J Thorac Cardiovasc Surg 128:850-859
39. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, Dumitrascu R, Seeger W, Knaus P, Schermuly RT, Eickelberg O 2007 Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 27:1072-1078
40. Kim YM, Reed W, Wu W, Bromberg PA, Graves LM, Samet JM 2006 Zn2+-induced IL-8 expression involves AP-1, JNK, and ERK activities in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 290:L1028-L1035
41. Samet JM, Graves LM, Quay J, Dailey LA, Devlin RB, Ghio AJ, Wu W, Bromberg PA, Reed W 1998 Activation of MAPKs in human bronchial epithelial cells exposed to metals. Am J Physiol 275(3 Pt 1):L551-L558
42. Farooq A, Zhou MM 2004 Structure and regulation of MAPK phosphatases. Cell Signal 16:769-779
43. Yamanouchi T, Moromizato H, Kojima S, Shinohara T, Sekino N, Minoda S, Miyashita H, Akaoka I 1994 Prevention of diabetes by thymic hormone in alloxan-treated rats. Eur J Pharmacol 257:39-46
44. Mizutani M, El-Fotoh M, Mori M, Ono K, Doi K, Awaya A, Matsumoto Y, Matsumoto Y, Onodera T 1996 In vivo administration of serum thymic factor (FTS) prevents EMC-D virus-induced diabetes and myocarditis in BALB/cAJcl mice. Arch Virol 141:73-83
45. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1-20
46. Nogueira-Silva C, Santos M, Baptista MJ, Moura RS, Correia-Pinto J 2006 IL-6 is constitutively expressed during lung morphogenesis and enhances fetal lung explant branching. Pediatr Res 60:530-536
47. Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J 2007 Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 292:L1473-L1479